Clinical considerations in Parkinson's disease cell therapy

Jun Xue¹, Yifan Wu¹, Yuting Bao¹, Minglai Zhao¹, Fangzhou Li¹, Jing Sun², Yimin Sun³, Jian Wang³, Liang Chen¹, Ying Mao⁴, Jeffrey S Schweitzer⁵, Bin Song⁶

Affiliations

¹ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China.
² Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China.
³ Institute of Neurology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China.
⁴ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China. Electronic address: maoying@fudan.edu.cn.
⁵ Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: jschweitzer1@mgh.harvard.edu.
⁶ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China. Electronic address: binsong@fudan.edu.cn.

PMID: 36402405
DOI: 10.1016/j.arr.2022.101792

Review

Clinical considerations in Parkinson's disease cell therapy

Jun Xue et al. Ageing Res Rev. 2023 Jan.

. 2023 Jan:83:101792.

doi: 10.1016/j.arr.2022.101792. Epub 2022 Nov 17.

Authors

Jun Xue¹, Yifan Wu¹, Yuting Bao¹, Minglai Zhao¹, Fangzhou Li¹, Jing Sun², Yimin Sun³, Jian Wang³, Liang Chen¹, Ying Mao⁴, Jeffrey S Schweitzer⁵, Bin Song⁶

Affiliations

¹ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China.
² Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China.
³ Institute of Neurology, National Clinical Research Center for Aging and Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China.
⁴ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; National Center for Neurological Disorders, Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Neurosurgical Institute of Fudan University, Shanghai Clinical Medical Center of Neurosurgery, Shanghai 200040, China. Electronic address: maoying@fudan.edu.cn.
⁵ Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: jschweitzer1@mgh.harvard.edu.
⁶ Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China; Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China. Electronic address: binsong@fudan.edu.cn.

PMID: 36402405
DOI: 10.1016/j.arr.2022.101792

Abstract

Cell replacement therapy is an area of increasing interest for treating Parkinson's disease (PD). However, to become a clinically practical option for PD patients, it must first overcome significant barriers, including establishment of safe and standardized surgical procedures, determination of appropriate perioperative medication regimens, demonstration of long-term graft survival and incorporation, and standardized, clinically meaningful follow-up measures. In this review, we will describe the current status of cell therapy for PD with special attention to these critical requirements, to define guideposts on the road to bring the benefit of this therapy to the Parkinson's clinic.

Keywords: Cell therapy; Clinical trial; Dopamine cells; Parkinson’s disease; Transplantation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no conflict of interest.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical considerations in Parkinson's disease cell therapy

Affiliations

Clinical considerations in Parkinson's disease cell therapy

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical